Children with the eye cancer retinoblastoma in a low-income country are at 16 times higher risk of dying at any time within three years of diagnosis than those in high-income countries, according to a new study published in The Lancet Global Health.
The research, led by the International Centre for Eye Health (ICEH) at the London School of Hygiene & Tropical Medicine (LSHTM), found stark differences in survival for children with retinoblastoma, the most common form of childhood eye cancer, between high-income and low-income countries.
Retinoblastoma is the most common and devastating eye cancer that affects children worldwide, and early diagnosis and treatment are critical to prevent death or the loss of an eye.
In high-income countries this risk has dropped dramatically over the last few decades, with death now rare due to robust diagnosis and treatment pathways, including specialist retinoblastoma centres.
The study, which is the largest and most geographically comprehensive on retinoblastoma to date, looked at survival data in 4,064 children with retinoblastoma from 149 countries (categorised as high, upper-middle, lower-middle and low-income) globally. These are estimated to be 50% of all new cases worldwide in 2017.
The team analysed the three-year survival rate for these children following their diagnosis, finding that over two-fifths (40%) of children die within three years of diagnosis in low-income countries, compared with fewer than one in 100 (1%) in high-income countries.
Professor Matthew Burton, Director of the ICEH at LSHTM, said: “This is a shocking result – highlighting the inequalities between high- and low-income countries for this disease. We cannot accept children having such a high risk of death in low-income settings from a disease that elsewhere is viewed as curable. We need to ensure that the reasons for this disparity are ascertained and policies enacted that close this survival gap.”
Despite the study showing that the main treatments for retinoblastoma (the removal of an eye, or enucleation, and intravenous chemotherapy) being available in all countries, several factors may be responsible for the reduced survival rate. Previous studies suggest that low-income countries are less likely to have specialised treatment centres containing sophisticated equipment and techniques such as MRI machines and targeted chemotherapy. Limited awareness among the general public and health care workers, and issues accessing treatment due to travel distance and cost are all suggested to contribute to worse outcomes and increased risk of death.
Dr Ido Didi Fabian, lead author and Principal Investigator of the Global Retinoblastoma Study Group at LSHTM, said: “We have always known there was a difference in outcomes between higher and lower income countries, but the differences we’re seeing in this study, the largest of its kind, are very worrying for children affected by retinoblastoma. Better awareness of the early signs, improving access to timely diagnosis, and implementing existing guidelines aimed at children in low- and middle-income countries, are critical to improving retinoblastoma outcomes worldwide.”
The work was made possible by the Retinoblastoma Network (Rb-NET), facilitated by ICEH, which allowed 260 retinoblastoma centres across the world to share data for the study. This collective data sharing could further lead to a live clinical data repository, strengthening evidence-based guidance on management of the condition.
The majority of existing evidence for retinoblastoma comes from high-income countries, despite patients in areas such as North America, Europe and Oceania representing less than 10% of global cases. The authors note that further research in low-income countries themselves is needed to identify the causes of this global disparity and improve outcomes.
The authors acknowledge limitations of the study, including that the cohort was a sample taken from a previous study (despite containing half of all cases worldwide for that year). The study also did not collect detailed data on treatment, for instance specific treatment protocols and complications. Future studies could include these sub-analyses.
For more information, please contact [email protected]
A copy of the paper is available upon request.
The Global Retinoblastoma Study Group. Global Retinoblastoma Outcome Study: Prospective Analysis of 4,064 Patients from 149 Countries. The Lancet Global Health.
Post-embargo link to the paper: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(22)00250-9/fulltext
Notes to Editors
- This work was supported by a grant from the Queen Elizabeth Diamond Jubilee Trust
- Countries were classified as high-, upper-middle-, lower-middle- and low-income based on the World Bank Country and Lending Groups for that fiscal year: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
The London School of Hygiene & Tropical Medicine (LSHTM) is a world-leading centre for research, postgraduate studies and continuing education in public and global health. LSHTM has a strong international presence with over 3,500 staff and 4,000 students working in the UK and around the world, and an annual research income of £180 million.
LSHTM is one of the highest rated research institutions in the UK, and is partnered with two MRC Units in The Gambia and Uganda. We received a Queen’s Anniversary Prize for Higher and Further Education in 2017 in recognition of our work on Ebola, and in 2022 for our response to COVID-19. Our mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice. We are committed to delivering world class research and education in a sustainable way and are working to achieve net zero by 2030.
Follow us on social media @LSHTM
The International Centre for Eye Health (ICEH) is a research and education group based at the London School of Hygiene & Tropical Medicine, working with an international network of partners. Our vision is Improving Eye Health Worldwide. Alumni from 188 countries have studied eye health courses at ICEH.
The Lancet Global Health
Global Retinoblastoma Outcome Study: Prospective Analysis of 4,064 Patients from 149 Countries.
Article Publication Date